Nippon Shinyaku and Atsena Therapeutics Enter into an Exclus…
News
July, 29 2021 • Articles
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
July 29th, 2021 - Source: Inside Philanthropy
Since its establishment in 1971 by a group of families affected by retinal disease, the Foundation Fighting Blindness has funded research into several of the most serious and common of these conditions, like macular degeneration and retinitis pigmentosa. The foundation grew to become the leading private funder of basic research into conditions that cause blindness and vision loss for more than 10 million Americans and millions more worldwide. In its 50 years in operation, the foundation has raised over $816 million to support research—including the identification of key genes linked to retinal diseases—that has enabled the launch of dozens of clinical trials to test possible treatments. All in all, a solid track record.
Click here for the rest of the article
The resulting company will operate under the name Opus Genet…
First oral presentation on PRODYGY at a major cell and gene …
Acquisition creates a leading, clinical-stage company focuse…
SPVN06 demonstrates continued favorable safety profile at 12…
Atsena Therapeutics Announces 12-Month Safety and Efficacy D…
Priority Review Voucher would be issued upon approval of OPG…
Priority Review Voucher would be issued upon approval of ATS…
Ascidian to receive $42 million in initial payment, and up t…
$1M TRAP award to support preclinical safety study for gene …
• First analysis from PHENOROD2, one of the largest prospec…
- Subretinal injection of ATSN-201 was well tolerated in all …